Sample Healthcare Paper on The Ebola Vaccine

Recently the World Health Organization reported that there was going to be enough supply of the experimental vaccine that is meant to control the outbreak of Ebola virus especially in the Democratic Republic of Congo. This is great news for many people in those African countries that have been affected by this devastating virus. The vaccine is known as V920 which was first used in Guineas during the massive outbreak in West Africa between the years of 2014-2016 (Branswell). This is a great milestone because it will be used by people who are in close contact with the affected ones. Such people include health workers and those who conduct safe burials. There is still hope that in the future the vaccine will prove 100 percent effective in the vaccination programs that will be carried out across those African countries.

Despite the milestone achieved with the discovery of this experimental vaccine, some issues might arise. The way this vaccine is being used it’s not the way a normal vaccination program works. Only people who have come into closer contact with the virus are the only ones who are being vaccinated. Unlike in a standard vaccination program the healthy population are the ones who are vaccinated. Administering the vaccine to those who have come into close contact with the virus allows a small time window for the vaccine to work. This is because the body should produce antibodies in a fast way compared to the way the virus is replicating its self in the body. Finally, it needs to be stored at a minus 80 degrees Celsius (Pultarova). This poses a great challenge for field hospitals and health teams operating in tropical forest. Some of these places can only be accessed using helicopters.

Works Cited

Branswell, Hellen. “A Spot Of Good News In Ebola Crisis: Vaccine Supplies Are Expected To Last.” STAT. N.p., 2019. Web. 28 Mar. 2019.

Pultarova, Tereza. “Here’s How Health Officials Plan To Use The Ebola Vaccine In New African Outbreak.” Live Science. N.p., 2018. Web. 28 Mar. 2019.